The field of oncology has been revolutionized by the advent of targeted therapies, shifting the paradigm from traditionally cytotoxic, non-specific treatments to a more personalized, precision-based approach. This article delves into the recent advancements and potential of targeted therapy in oncology.
Unlike conventional chemotherapy, targeted therapy works by interfering with specific proteins that help tumors grow and spread, thereby minimizing damage to healthy cells. It focuses on the molecular and cellular changes specific to cancer, which includes overactive signaling pathways, mutations driving cancer growth, and tumor angiogenesis.
Recent years have seen a surge in the development and approval of targeted therapies. Tyrosine kinase inhibitors (TKIs), such as imatinib and erlotinib, have shown success in treating chronic myeloid leukemia and non-small cell lung cancer, respectively. Monoclonal antibodies like trastuzumab have been effective against HER2-positive breast cancer. Additionally, breakthroughs in immunotherapy, including immune checkpoint inhibitors and CAR-T cell therapy, have opened new avenues in treating various malignancies.
The potential of targeted therapy is vast, with ongoing research exploring novel targets and combination therapies. However, challenges persist. Resistance to therapy, both primary and acquired, poses a significant hurdle. Heterogeneity within tumors also complicates treatment, as different cells may respond variably to the same therapy. Furthermore, the high cost of these therapies can limit accessibility.
In conclusion, targeted therapy heralds a new era in cancer treatment, offering the promise of increased specificity and reduced toxicity compared to traditional chemotherapy. While challenges persist, continued research and innovation hold the key to unlocking its full potential, paving the way for a more personalized and effective approach to cancer treatment.
1.
Discovery reveals protein involved in Parkinson's disease also drives skin cancer
2.
The prognosis of the Slovakian PM; Kate Middleton's treatment; and drug test cheating.
3.
We Don't Always Know What's 'Best' for Our Patients
4.
New tumor therapy approach reduces costs and side effects while increasing accessibility
5.
Dual-action mRNA vaccine takes aim at aggressive skin cancer
1.
The Evolving Arsenal: A 2025 Review of Antibody-Drug Conjugates and the Future of Precision Oncology
2.
Case Study: Combining Targeted Therapy with Immunotherapy for Metastatic Melanoma
3.
Anion Gap: The Simple Calculation That Reveals Much About Your Health
4.
Contemporary Methods in Hematology Across Clinical Settings
5.
Unlocking the Potential of Cytarabine: A New Era of Cancer Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
3.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
4.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option
5.
Current Scenario of Cancer- Palliative Care to Close the Care Gap
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation